Publication of Pricing Supplement

Summary by AI BETAClose X

Close Brothers Finance PLC has published a pricing supplement detailing the issuance of £250,000,000 of 5.750 per cent. fixed rate notes due 10 September 2031, guaranteed by Close Brothers Limited under its Euro Medium Term Note Programme. These notes were issued pursuant to base admission particulars dated 27 May 2026. The announcement clarifies that this information is not for distribution in or into the United States or to U.S. persons, and the securities have not been registered under the U.S. Securities Act of 1933.

Disclaimer*

Close Brothers Finance PLC
09 June 2026
 


9 June 2026

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR ITS TERRITORIES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS OR OTHERWISE THAN TO PERSONS TO WHOM IT CAN LAWFULLY BE DISTRIBUTED

CLOSE BROTHERS FINANCE PLC

PUBLICATION OF PRICING SUPPLEMENT IN RELATION TO THE ISSUE BY CLOSE BROTHERS FINANCE PLC OF £250,000,000 5.750 PER CENT. FIXED RATE NOTES DUE 10 SEPTEMBER 2031 (THE "NOTES") GUARANTEED BY CLOSE BROTHERS LIMITED UNDER THE EURO MEDIUM TERM NOTE PROGRAMME

Close Brothers Finance plc (the "Issuer") today announces that it has published the pricing supplement dated 8 June 2026 setting out details of the £250,000,000 5.750 per cent. Fixed Rate Notes due 10 September 2031 (the "Pricing Supplement").

The Notes were issued pursuant to the base admission particulars dated 27 May 2026, including all documents incorporated therein by reference (together, the "Admission Particulars"), in connection with the Euro Medium Term Note Programme of Close Brothers Finance plc. The Pricing Supplement should be read in conjunction with the Admission Particulars.

To view the Pricing Supplement, please paste the following URL into the address bar of your browser: http://www.rns-pdf.londonstockexchange.com/rns/6199H_1-2026-6-9.pdf

For further information, please contact:

Maritz Carvalho
Head of Investor Relations
Close Brothers Limited
10 Crown Place
London EC2A 4FT
+44 (0)333 321 6100

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in the Pricing Supplement and the Admission Particulars may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Pricing Supplement and the Admission Particulars) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Pricing Supplement and the Admission Particulars is not addressed. Prior to relying on the information contained in the Pricing Supplement and the Admission Particulars, you must ascertain from the Pricing Supplement and the Admission Particulars whether or not you are part of the intended addressees of the information contained therein.

In particular, neither this announcement nor the Pricing Supplement nor the Admission Particulars shall constitute an offer to sell or the solicitation of an offer to buy securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities law of any such jurisdiction.

The securities described in the Pricing Supplement and the Admission Particulars have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") or any relevant securities laws of any state of the United States. The securities may not be offered or sold within the United States or to or for the account or benefit of U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The Pricing Supplement and the Admission Particulars may not be accessed from, or transmitted in or into, the United States.

Your right to access this service is conditional upon complying with the above requirements.

END.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings